Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

gain on disposal of investment in Vertex ($23.5 million), and tax effect of adjustments; and

d)Depreciation: Depreciation of $85.2 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


 

Unaudited results for the nine months to September 30, 2010

Non GAAP reconciliation

US GAAP Adjustments Non GAAP Acquis Divestments, Amorti itions & reorgan September -zation integr -izations & Reclas September 9 months to, 30, & asset -ation discontinued -sify 30, 2010 impairments activ operations deprec 2010 -ities -iation (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 2,539.9 - - - - 2,539.9 Costs and expenses: Cost of product sales 333.7 - - (21.9) (8.6) 303.2 Research and development 475.9 - (45.0) - (11.6) 419.3 Selling, general and administrative 1,106.7 (142.3) - - (49.0) 915.4 Gain on sale of product rights (4.1) - - 4.1 - - Reorganization costs 23.3 - - (23.3) - - Integration and acquisition costs 6.4 - (6.4) - - - Depreciation - - - - 69.2 69.2 Total operating expenses 1,941.9 (142.3)(51.4) (41.1) - 1,707.1 Operating income 598.0 142.3 51.4 41.1 - 832.8 Interest income 1.9 - - - - 1.9 Interest expense (25.6) - - - - (25.6) Other income/(expense), net 9.0 - - (11.1) - (2.1) Total other expense, net (14.7) - - (11.1) - (25.8) Income before income taxes and equity in earnings of equity method investees 583.3 142.3 51.4 30.0 - 807.0 Income taxes (160.8) (29.4) (3.6) (9.1) - (202.9) Equity in earnings of equity method investees, net of tax 0.2 - - - - 0.2 Net income 422.7 112.9 47.8 20.9 - 604.3 Impact of convertible debt, net of tax 25.2 - - - - 25.2 Numerator for diluted EPS 447.9 112.9 47.8 20.9 - 629.5 Weighted average number of shares (millions) - diluted 589.7 - - - - 589.7 Diluted earnings per ADS 228.0c 57.3c 24.3c 10.6c - 320.2c

The following items are included in Adjustments:

'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... October 02, 2014 Freeslate, ... research solutions for biopharmaceutical development, today announced highlights ... 24, 2014 at GlaxoSmithKline (GSK) in Ware, UK. ... of best practices in high throughput research and ... leaders gathered together to discuss the challenges and ...
(Date:10/2/2014)... The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama's BRAIN (Brain Research ... effort to revolutionize our understanding of the human ...
(Date:10/2/2014)... , Oct. 2, 2014  NKT Therapeutics ... Administration has granted Fast Track designation to NKTT120, ... treatment of sickle cell disease.  NKTT120 is a ... a regulatory T cell that has been demonstrated ... in preclinical models of sickle cell disease.  Fast ...
(Date:10/1/2014)... 01, 2014 METTLER TOLEDO’s newly improved ... precision balances as well as a dual range ... performance, the new SmartPan™ weighing pan delivers results up ... On all balances, ergonomic design details mean users no ... working for long periods in front of the balance. ...
Breaking Biology Technology:Freeslate European Summit Highlights Best Practices in High Throughput Research and Data Management 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3
... Oct. 16 Compendia Bioscience, Inc.,today announced ... Premium Edition, a high-value product extension of ... Oncomine Research,Premium Edition includes custom gene filters, ... support for Oncomine Concepts Map,including the ability ...
... DRRX ) announced today that it will be hosting ... at 12:00 p.m. Eastern Time. A live audio,webcast of ... and will,be available by accessing DURECT,s homepage at ... to participate during the,live webcast, the call will be ...
... will receive milestones and ... by Altair - Altair to conduct clinical development ... FRANCISCO, Oct. 16 ,Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Inc., a new venture,capital-funded biotechnology company, has been created to ...
Cached Biology Technology:Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 3Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 4Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 5
(Date:10/2/2014)... 2014 CARTES ... identification and mobility which is being held at ... 6 November 2014, is proud to announce the ... agency FABERNOVEL.        (Logo: http://photos.prnewswire.com/prnh/20140526/689195) ... to support innovative businesses from the digital security ...
(Date:10/2/2014)... 2014 CARTES SECURE CONNEXIONS 2014 Conference: ... Sector CARTES SECURE CONNEXIONS 2014 is being held ... 6 November 2014. This 29 th  international meeting for ... mobility, will bring together the global community of a ... programme of conferences will set the pace for the ...
(Date:10/1/2014)... inheritance, showing for the first time that offspring can ... at least., This confronting idea, known as telegony, dates ... the early 20th Century with the advent of genetics., ... Crean, Professor Russell Bonduriansky and Dr Anna Kopps manipulated ... They found that the size of the young was ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 2CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 3CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 4CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 5CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4Semen secrets: How a previous sexual partner can influence another male's offspring 2
... multiple languages, cultures, races and religions, but among this diversity ... more united through our ears. In fact Mihailo Antovic, ... proposes that our musical conceptualization brings together a world of ... of distinct ethnic backgrounds and languages in his home of ...
... registration and abstract submission is now open at ... to be held in the Middle-East and Africa region. ... part of a new series of ,IOF Regionals, around ... energize research efforts in the region while offering advanced ...
... A drug already approved for people with cancer ... form of dementia, UT Southwestern Medical Center researchers report. ... a first-generation drug for the prevention and treatment of ... for which there is no treatment," said Dr. Joachim ...
Cached Biology News:1 world, 1 sound 21 world, 1 sound 3Cancer drug holds promise as first treatment for common, inherited dementia 2
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: